

COG Protocols UPH and SJCH			
Study	Description	UPH	SJCH
AALL05B1-	A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens	X	X
AALL07P1-	A Phase II Pilot Trial of Bortezomib (PS-341, Velcade®, IND# 58,443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)		X
AALL08B1-	Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)	X	X
AALL0932-	Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy)	X	X
AALL1131	A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL)	X	X
AALL1331-	Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL): A Groupwide Phase III Study		X
AAML08B1-	Biology Study of Transient Myeloproliferative Disorder (TMD) in Children with Down Syndrome (DS)		X
AAML0431	The Treatment of Down Syndrome Children with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Under the Age of 4 Years: A Groupwide Phase III Study		X
AAML0531-	A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg®) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults		X
AAML0631	Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® IND# 103, 331) during Consolidation: A Phase III Study Limited to COG institutions in the United States & Canada		X
AAML1031-	A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC# 681239, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD		X
AAML1331	A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic		X
ACCL0933-	A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML): A Groupwide Phase III Study		X
ACCL1033	A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL: A Group-wide Non-Therapeutic Study	X	X
ACCL1034-	Impact of Cleansing with Chlorhexidine Gluconate (CHG) on Reducing Central Line Associated Bloodstream Infection (CLABSI) and Acquisition of Multi-drug Resistant Organisms (MDRO) in Children with Cancer or Those Receiving Allogeneic Hematopoietic Cell Transplantation	X	X
ACCRN07-	Network (CCRN)	X	X
ACNS0334-	A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children < 36 months Old with Intensive Induction Chemotherapy with Methotrexate Followed by Consolidation with Stem Cell Rescue vs. the Same Therapy Without Methotrexate: A Phase III Group-Wide Study		X
ACNS0821-	Temozolomide with Irinotecan versus Temozolomide, Irinotecan plus Bevacizumab (NSC# 704865, BB-IND# 7921) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial: A Groupwide Phase II Study	X	
ACNS1123-	Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT): A Groupwide Phase II Study	X	
ACNS1221-	A Phase II Study For The Treatment Of Non-Metastatic Nodular Desmoplastic Medulloblastoma In Children Less Than 4 Years Of Age: A Groupwide Phase II Study	X	X
AEPI05N1-	Carcinogen Metabolism, DNA Repair, Parental Exposures and Retinoblastoma: A Groupwide Non-Therapeutic Study		X
AEWS07B1-	A COG Study for Collecting and Banking Ewing Sarcoma Specimens	X	X

AEWS07P1-	A Pilot Study of Chemotherapy Intensification by Adding Vincristine, Topotecan, and Cyclophosphamide to Standard Chemotherapy Agents with an Interval Compression Schedule in Newly Diagnosed Patients with Localized Ewing Sarcoma Family of Tumors		X
AEWS1031-	A Phase III Randomized Trial of Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma: A Groupwide Phase III Study	X	X
AEWS1221-	Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma: An Intergroup NCTN Phase II Study	X	X
AGCT0521-	Treatment of Recurrent or Resistant Pediatric Malignant Germ Cell Tumors with Paclitaxel, Ifosfamide and Carboplatin: A Groupwide Phase II Study		X
AHEP0731-	Treatment of Children with All Stages of Hepatoblastoma with Temsirolimus (IND#122782, NSC#683864) Added to High Risk Stratum Treatment: A Groupwide Phase III Study	X	X
AHOD03P1-	Treatment of Children with Newly-Diagnosed Low Stage Lymphocyte Predominant Hodgkin Disease (LPHD): A Groupwide Pilot Study		X
AHOD0431-	A Phase III Study for the Treatment of Children and Adolescents With Newly Diagnosed Low Risk Hodgkin Disease		X
AHOD0831-	A Non-Randomized Phase III Study of Response Adapted Therapy for the Treatment of Children with Newly Diagnosed High Risk Hodgkin Lymphoma: A Groupwide Phase III Study		X
AHOD1221-	Gemcitabine for Pediatric and Young Adult Patients with Relapsed or Refractory Hodgkin Lymphoma		X
AHOD1331	A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents: A	X	
ALTE05N1-	Umbrella Long-Term Follow-Up Protocol		X
ANBL00B1-	Neuroblastoma Biology Studies	X	X
ANBL0531	Response- and Biology-Based Therapy for Intermediate-risk Neuroblastoma: A Groupwide Phase III Study		X
ANBL0532-	Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma: A Groupwide Phase III Study		X
ANBL1221-	A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864, IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 764038, IND# 4308) in Children with Refractory, Relapsed or Progressive Neuroblastoma		X
ANBL1232-	Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma. A Groupwide Historically Controlled Phase III Study	X	
ANHL04B1	Rare and Cutaneous Non-Hodgkin Lymphoma Registry		X
ANHL1131-	Intergroup Trial for Children or Adolescents with B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients		X
AOST0331-	A Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment Strategies for Resectable Osteosarcoma Based on Histological Response to Pre-Operative Chemotherapy (IND# 12697): A Phase III Intergroup Study		X
AOST06B1-	A Children's Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens		X
AOST1321	Phase II Study of Denosumab (IND #127430, NSC# 744010), a RANK Ligand Antibody, for Recur	X	X
APEC14B1	The Project: Everychild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study	X	
AREN03B2	Renal Tumors Classification, Biology, and Banking Study	X	X
ARST0332-	Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age: A Groupwide Phase III Study		X
ARST0531-	Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma (RMS): A Groupwide Phase III Study		X

ARST1321-	Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)	X	X
9902-	A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol		X